About Sapphire Therapeutics
Sapphire Therapeutics was founded in 2008 and is headquartered in Iselin, United States. Focus is placed on the development of small molecule drugs targeting metabolic and oncologic disorders within the biotechnology sector. The pipeline features anamorelin in phase 2 trials for cancer cachexia, ipamorelin in phase 2 for postoperative ileus, and ST-114 in phase 1 for opioid-induced bowel dysfunction. Operations center on advancing these therapeutic candidates through clinical stages.
- Headquarter Iselin, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Sapphire Therapeutics
Detailed funding history for Sapphire Therapeutics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Sapphire Therapeutics
Sapphire Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Helsinn.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Oncology therapeutics are developed, manufactured, and commercialized by Helsinn.
|
Locked | Locked | Locked |
Investor details for Sapphire Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sapphire Therapeutics
Investment portfolio details for Sapphire Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sapphire Therapeutics
Detailed financials for Sapphire Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sapphire Therapeutics Comparisons
Peer comparison for Sapphire Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sapphire Therapeutics
Detailed competitors of Sapphire Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sapphire Therapeutics
Complete news archive for Sapphire Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sapphire Therapeutics
Sapphire Therapeutics was founded in 2008.
Sapphire Therapeutics is headquartered in Iselin, United States. It is registered at Iselin, New Jersey, United States.
Sapphire Therapeutics was founded in 2008 and is headquartered in Iselin, United States. Focus is placed on the development of small molecule drugs targeting metabolic and oncologic disorders within the biotechnology sector. The pipeline features anamorelin in phase 2 trials for cancer cachexia, ipamorelin in phase 2 for postoperative ileus, and ST-114 in phase 1 for opioid-induced bowel dysfunction. Operations center on advancing these therapeutic candidates through clinical stages.
Sapphire Therapeutics has 1 investor. Key investors include Helsinn.